Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia : A Five-Year Longitudinal Study
© 2024. The Author(s)..
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is associated with huge clinical and economic burden in the Kingdom of Saudi Arabia (KSA) which can be curtailed by efficacious treatment. In order to achieve this, current treatment pathways for T2DM and associated costs need to be assessed.
METHODS: A longitudinal cohort review was conducted to collect country-specific and patient-specific clinical data, over a minimum observation period of 5 years in the KSA. Patient demographics, clinical characteristics and treatment patterns were recorded. The IQVIA Core Diabetes Model (CDM) version 9.5 Plus was used to assess the burden of illness, which included long-term projections of clinical (life expectancy [LE], quality-adjusted life-years [QALYs], event rates of diabetes-related complications) and direct medical cost (per-patient annual or lifelong [50 years]) outcomes of the most commonly used first-line (1st-line) regimens for T2DM from a payer perspective in the KSA.
RESULTS: Data were collected from a subpopulation of 638 patients from 15 participating centres. There was an equal gender representation with a majority of the patients belonging to Arabian/Saudi ethnicity (71.0%). Biguanides (81.5%), sulfonylureas (51.6%), dipeptidyl peptidase 4 (DPP4) inhibitors (26.2%) and fast-acting insulins (17.2%) were the most prescribed 1st-line agents. The most frequently used 1st-line regimens resulted in an estimated LE of 25-28 years, QALYs of 18-21 years and lifelong total cost of illness of 201,377-437,371 Saudi Arabian riyal (53,700-116,632 US dollars).
CONCLUSION: Our study addresses gaps in the current research by providing a complete landscape of baseline demographic, clinical characteristics and treatment patterns from a heterogeneous group of patients with T2DM in the KSA. Additionally, the burden of illness analysis using CDM showed substantially higher cost of T2DM care from a payer perspective in the KSA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 3 vom: 20. Feb., Seite 1120-1150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
AlHarbi, Mohammed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burden of illness |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-023-02772-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367314428 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367314428 | ||
| 003 | DE-627 | ||
| 005 | 20240229144123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02772-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM367314428 | ||
| 035 | |a (NLM)38240948 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a AlHarbi, Mohammed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia |b A Five-Year Longitudinal Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a INTRODUCTION: Type 2 diabetes mellitus (T2DM) is associated with huge clinical and economic burden in the Kingdom of Saudi Arabia (KSA) which can be curtailed by efficacious treatment. In order to achieve this, current treatment pathways for T2DM and associated costs need to be assessed | ||
| 520 | |a METHODS: A longitudinal cohort review was conducted to collect country-specific and patient-specific clinical data, over a minimum observation period of 5 years in the KSA. Patient demographics, clinical characteristics and treatment patterns were recorded. The IQVIA Core Diabetes Model (CDM) version 9.5 Plus was used to assess the burden of illness, which included long-term projections of clinical (life expectancy [LE], quality-adjusted life-years [QALYs], event rates of diabetes-related complications) and direct medical cost (per-patient annual or lifelong [50 years]) outcomes of the most commonly used first-line (1st-line) regimens for T2DM from a payer perspective in the KSA | ||
| 520 | |a RESULTS: Data were collected from a subpopulation of 638 patients from 15 participating centres. There was an equal gender representation with a majority of the patients belonging to Arabian/Saudi ethnicity (71.0%). Biguanides (81.5%), sulfonylureas (51.6%), dipeptidyl peptidase 4 (DPP4) inhibitors (26.2%) and fast-acting insulins (17.2%) were the most prescribed 1st-line agents. The most frequently used 1st-line regimens resulted in an estimated LE of 25-28 years, QALYs of 18-21 years and lifelong total cost of illness of 201,377-437,371 Saudi Arabian riyal (53,700-116,632 US dollars) | ||
| 520 | |a CONCLUSION: Our study addresses gaps in the current research by providing a complete landscape of baseline demographic, clinical characteristics and treatment patterns from a heterogeneous group of patients with T2DM in the KSA. Additionally, the burden of illness analysis using CDM showed substantially higher cost of T2DM care from a payer perspective in the KSA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Burden of illness | |
| 650 | 4 | |a Core diabetes model | |
| 650 | 4 | |a Kingdom of Saudi Arabia | |
| 650 | 4 | |a Real-world | |
| 650 | 4 | |a Saudi Arabia | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
| 700 | 1 | |a Othman, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Nahari, Ahmed Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Jedai, Ahmed Hamdan |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadras, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Almalky, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a AlAzmi, Fayez |e verfasserin |4 aut | |
| 700 | 1 | |a Almudaiheem, Hajer Yousef |e verfasserin |4 aut | |
| 700 | 1 | |a AlShubrumi, Hamad |e verfasserin |4 aut | |
| 700 | 1 | |a AlSwat, Hameed |e verfasserin |4 aut | |
| 700 | 1 | |a AlSahafi, Homaid |e verfasserin |4 aut | |
| 700 | 1 | |a Sindi, Kamelia |e verfasserin |4 aut | |
| 700 | 1 | |a Basaikh, Khadija |e verfasserin |4 aut | |
| 700 | 1 | |a AlQahtani, Majed |e verfasserin |4 aut | |
| 700 | 1 | |a Lamotte, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Yahia, Moataz |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Mohamed El-Khedr |e verfasserin |4 aut | |
| 700 | 1 | |a AlMutlaq, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a AlRoaly, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a AlZelaye, Somaya |e verfasserin |4 aut | |
| 700 | 1 | |a AlGhamdi, Zein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 3 vom: 20. Feb., Seite 1120-1150 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:3 |g day:20 |g month:02 |g pages:1120-1150 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-023-02772-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 3 |b 20 |c 02 |h 1120-1150 | ||